The short-term use of erythropoetin-stimulating agents: Impact on the biochemical recurrence of prostate cancer

BJU International

Volumn 108, Issue 10, 2011, Pages 1582-1587

  Djavan, Bob ^a   Laze, Juliana ^a   Eckersberger, Elisabeth ^a   Finkelstein, Julia ^a   Agalliu, Ilir ^b   Lepor, Herbert ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

biochemical recurrence; erythropoietin; ESAs; prostate cancer; radical prostatectomy; survival

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; BIOCHEMICAL COMPOSITION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG USE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK BENEFIT ANALYSIS; SHORT COURSE THERAPY; SURVIVAL RATE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ERYTHROPOIETIN; HEMATINICS; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS;

EID: 80255137122     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10173.x     Document Type: Article

References (25)

1. Seidenfeld J, Piper M, Flamm C, et al,. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001; 93: 1204-14 (Pubitemid 32816195)
2. Leyland-Jones B, Semiglazov V, Pawlicki M, et al,. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-72
3. Littlewood TJ, Kallich JD, San Miguel J, Hendricks L, Hedenus M,. Efficacy of darbepoetin alfa in alleviating fatigue and the effect of fatigue on quality of life in anemic patients with lymphoproliferative malignancies. J Pain Symptom Manag 2006; 31: 317-25
4. Ferrandina G, Distefano M, Smaniotto D, et al,. Anemia in patients with locally advanced cervical carcinoma administered preoperative radiochemotherapy: association with pathological response to treatment and clinical outcome. Gyn Onc 2006; 103: 500-5 (Pubitemid 44602160)
5. Henke M, Laszig R, Rübe C, et al,. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60 (Pubitemid 37324251)
6. Wright JR, Ung YC, Julian JA, et al,. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Onc 2007; 25: 1027-32 (Pubitemid 46596751)
7. Bohlius J, Schmidlin K, Brillant C, et al,. Erythropoietin or Darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; 8: CD007303
8. Glaspy J, Crawford J, Vansteenkiste J, et al,. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-15
9. Weltert L, D'Alessandro S, Nardella S, et al,. Properative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg 2010; 139: 621-6
10. U.S. Food and Drug Administration (FDA) Drug Safety Communication. Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp. Last retrieved 3.24.2010. Available at:. Accessed 26 April 2010
11. Sultan R, Slova D, Thiel B, Lepor H,. Time to return to work and physical activity following open radical retropubic prostatectomy. J Urol 2006; 176: 1420-3 (Pubitemid 44307196)
12. Shen S, Lepor H, Yaffee R, Taneja SS,. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 2005; 173: 777-80 (Pubitemid 40239340)
13. Hosmer DW, Lemeshow S,. Applied Survival Analysis: Regression Modeling to Time to Event Data. New York: Wiley, John & Sons, Inc., 1999
14. Cox DR,. Regression models with life-tables (with discussion). J Roy Statistic Soc Ser B 1972; 34: 187-220
15. Rosenblum N, Levine MA, Handler T, Lepor H,. The role of preoperative epoetin alfa in men undergoing radical retropubic prostatectomy. J Urol 2000; 163: 829-33 (Pubitemid 30091626)
16. Nieder AM, Rosenblum N, Lepor H,. Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. Urology 2001; 57: 737-41
17. McCullough PA, Lepor NE,. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med 2005; 6: 1-10 (Pubitemid 40458381)
18. Lepor H, Lipkin M, Slova D,. The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. Urology 2010; 75: 1424-8
19. Singh AK, Szczech L, Tang KL, et al,. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006; 355: 2085-98 (Pubitemid 44749317)
20. Stowell CP, Jones SC, Enny C, Langholff W, Leitz G,. An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Spine (Phila Pa 1976) 2009; 34: 2479-85
21. AApro M, Osterwalder B, Scherhag A, Burger HU,. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 2009; 101: 1961-71
22. Bennett CL, Silver SM, Djulbegovic B, et al,. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-24 (Pubitemid 351397066)
23. Bohlius J, Schmidlin K, Brillant C, et al,. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomized trials. Lancet 2009; 373: 1532-42
24. Henke M, Mattern D, Pepe M, et al,. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006; 24: 4708-13 (Pubitemid 46630934)
25. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC,. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003; 169: 517-23 (Pubitemid 36132976)